Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Northwestern Medicine Cancer Center Warrenville

6 abstracts

Abstract
Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.
Org: Miami Cancer Institute, Baptist Health South Florida, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, CHUM,
Abstract
Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ.
Org: Columbia University Irving Medical Center, New York, NY, USA, Sapience Therapeutics, Sapience Therapeutics, Inc., Columbia University Medical Center, BioForum Ltd.,
Abstract
Hope drives quality of life in patients with brain metastases, but the hope center remains elusive: An analysis of NRG-CC003.
Org: Sharei Zedek Hospital, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Northwestern Medicine Cancer Center Warrenville, Northwestern Medicine Proton Center, Baptist Health South Florida,
Abstract
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.
Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Northwestern Medicine Cancer Center Warrenville, University of Chicago, The University of Chicago Medicine Center for Advanced Care at Orland Park,
Abstract
Retrospective analysis of NUT carcinoma: The Northwestern experience.
Org: Northwestern Medicine Cancer Center Warrenville, Northwestern University-Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Abstract
The clinical impact of soluble natural killer cell group 2-member D (NKG2D) receptor ligands on tumor tumorigenicity and anti-tumor immunity.
Org: Northwestern Medicine Cancer Center Warrenville, Bristol Myers Squibb, Department of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,